Oppenheimer & Co’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $376K | Sell |
5,993
-418
| -7% | -$29.1K | ﹤0.01% | 1300 |
|
|
2025
Q4 | $425K | Sell |
6,411
-14,923
| -70% | -$965K | 0.01% | 1134 |
|
|
2025
Q3 | $1.44M | Sell |
21,334
-158
| -0.7% | -$12.5K | 0.02% | 729 |
|
|
2025
Q2 | $1.88M | Buy |
21,492
+267
| +1% | +$20.9K | 0.02% | 602 |
|
|
2025
Q1 | $1.45M | Buy |
21,225
+974
| +5% | +$79.5K | 0.02% | 653 |
|
|
2024
Q4 | $1.57M | Sell |
20,251
-12,598
| -38% | -$933K | 0.02% | 627 |
|
|
2024
Q3 | $2.2M | Sell |
32,849
-1,745
| -5% | -$143K | 0.03% | 521 |
|
|
2024
Q2 | $3.92M | Buy |
34,594
+285
| +0.8% | +$36K | 0.06% | 324 |
|
|
2024
Q1 | $4.76M | Sell |
34,309
-3,754
| -10% | -$472K | 0.08% | 282 |
|
|
2023
Q4 | $4.72M | Sell |
38,063
-7,155
| -16% | -$731K | 0.09% | 267 |
|
|
2023
Q3 | $4.22M | Sell |
45,218
-518
| -1% | -$58.4K | 0.09% | 264 |
|
|
2023
Q2 | $5.88M | Buy |
45,736
+4,627
| +11% | +$560K | 0.12% | 201 |
|
|
2023
Q1 | $4.78M | Sell |
41,109
-4,561
| -10% | -$511K | 0.1% | 238 |
|
|
2022
Q4 | $5.17M | Buy |
45,670
+6,238
| +16% | +$685K | 0.12% | 214 |
|
|
2022
Q3 | $3.18M | Sell |
39,432
-140
| -0.4% | -$11.9K | 0.07% | 316 |
|
|
2022
Q2 | $2.95M | Buy |
39,572
+480
| +1% | +$43.8K | 0.06% | 351 |
|
|
2022
Q1 | $5M | Buy |
39,092
+48
| +0.1% | +$5.25K | 0.09% | 276 |
|
|
2021
Q4 | $5.24M | Sell |
39,044
-108
| -0.3% | -$15.5K | 0.09% | 252 |
|
|
2021
Q3 | $5.35M | Sell |
39,152
-2,212
| -5% | -$279K | 0.1% | 234 |
|
|
2021
Q2 | $4.42M | Buy |
41,364
+2,848
| +7% | +$274K | 0.08% | 291 |
|
|
2021
Q1 | $3.46M | Sell |
38,516
-7,448
| -16% | -$699K | 0.07% | 328 |
|
|
2020
Q4 | $4.25M | Sell |
45,964
-16,008
| -26% | -$1.43M | 0.09% | 259 |
|
|
2020
Q3 | $6.39M | Buy |
61,972
+27,360
| +79% | +$2.86M | 0.16% | 138 |
|
|
2020
Q2 | $3.51M | Buy |
34,612
+7,928
| +30% | +$709K | 0.09% | 251 |
|
|
2020
Q1 | $1.8M | Buy |
26,684
+7,468
| +39% | +$465K | 0.05% | 364 |
|
|
2019
Q4 | $1.05M | Buy |
19,216
+4,916
| +34% | +$233K | 0.03% | 610 |
|
|
2019
Q3 | $534K | Buy |
14,300
+2,396
| +20% | +$93.1K | 0.01% | 774 |
|
|
2019
Q2 | $446K | Sell |
11,904
-130,736
| -92% | -$4.11M | 0.01% | 859 |
|
|
2019
Q1 | $4.25M | Buy |
142,640
+49,548
| +53% | +$1.74M | 0.11% | 206 |
|
|
2018
Q4 | $2.79M | Buy |
93,092
+79,964
| +609% | +$2.54M | 0.09% | 262 |
|
|
2018
Q3 | $469K | Buy |
13,128
+2,520
| +24% | +$78.1K | 0.01% | 891 |
|
|
2018
Q2 | $252K | Buy |
+10,608
| New | +$225K | 0.01% | 1129 |
|
Other funds holding DXCM
VCM
VPM
Oppenheimer & Co's DXCM Position: Q1 2026 in Review
Oppenheimer & Co reduced its DexCom (DXCM) stake by 6.5% in Q1 2026, selling an estimated $29.1K and leaving 5,993 shares worth $376K. The position accounts for ﹤0.01% of the portfolio, ranked #1300.
Oppenheimer & Co first reported a position in DXCM in Q2 2018 and has held it in 32 quarters since. The position peaked at $6.39M in Q3 2020. 957 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Oppenheimer & Co held 5,993 shares of DexCom worth $376K as of Q1 2026.
- Oppenheimer & Co sold 418 DexCom shares in Q1 2026, an estimated $29.1K.
- DexCom made up ﹤0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1300 holding.
- Oppenheimer & Co first reported a position in DexCom in Q2 2018 and has held it in 32 quarters since.
- Oppenheimer & Co's DexCom position peaked at $6.39M in Q3 2020.
- 957 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.